Bassan Abraham's Stock Option Grant at Rani Therapeutics Holdings, Inc.

Bassan Abraham, a director of Rani Therapeutics Holdings, Inc., was granted 100,000 stock options on October 23, 2025. The options, which are for Class A Common Stock, have an exercise price of $2.09 and will expire on October 22, 2035. The shares subject to this option will vest over a three-year period, with one-third of the shares vesting on October 23, 2026, and one thirty-sixth of the shares vesting each month thereafter, contingent on Bassan Abraham's continuous service with the company through each vesting date. This filing is a Form 4, indicating a change in beneficial ownership.